Indication

Treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.

Medicine details

Medicine name:
bimekizumab (Bimzelx)
SMC ID:
SMC2410
Pharmaceutical company
UCB Pharma Ltd
BNF chapter
Skin
Submission type
Abbreviated
Publication due date:
08 November 2021